Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vein Thrombosis Clear all
Terminated Phase 3 Interventional Results available

Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein

NCT01887717
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TheraSphere®, Sorafenib
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 10, 2026, 1:36 PM EDT
Completed Phase 3 Interventional

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

NCT00694382
View directory record Official record
Conditions
Venous Thromboembolism, Cancer
Interventions
Semuloparin sodium, Placebo (for semuloparin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
48
States / cities
Birmingham, Alabama • Casa Grande, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 10, 2026, 1:36 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients

NCT04252651
View directory record Official record
Conditions
Inflammatory Response, Multi Organ Failure, Nosocomial Infection, Deep Vein Thrombosis
Interventions
Blood Draw
Other
Lead sponsor
Joseph M. Still Research Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 10, 2026, 1:36 PM EDT
Terminated No phase listed Observational

Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging

NCT01717937
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Retinopathy, Hypertensive Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion
Interventions
Phase variance optical coherence tomography (PV-OCT)
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 10, 2026, 1:36 PM EDT
Completed Phase 2Phase 3 Interventional Results available

To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions

NCT00493064
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Nicotinic acid, Prednisolone acetate
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 10, 2026, 1:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Minocycline to Treat Branch Retinal Vein Occlusion

NCT01468831
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Minocycline, Placebo, Bevacizumab
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 10, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT04740905
View directory record Official record
Conditions
Macular Edema, Branch Retinal Vein Occlusion
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 10, 2026, 1:36 PM EDT
Terminated Phase 2 Interventional

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

NCT00981903
View directory record Official record
Conditions
Venous Thromboembolism, Cancer
Interventions
Tinzaparin sodium
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 10, 2026, 1:36 PM EDT
Recruiting Phase 3 Interventional

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

NCT07015905
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
REGN7508, Apixaban, Enoxaparin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Sheffield, Alabama • Riverside, California • Englewood, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 10, 2026, 1:36 PM EDT
Completed No phase listed Observational

The Roles of Tissue Factor in Malignant Gliomas

NCT00201903
View directory record Official record
Conditions
Venous Thromboembolism, Brain Tumors
Interventions
Not listed
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Detroit, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 10, 2026, 1:36 PM EDT
Completed No phase listed Observational

Incidence of Venous Thromboembolism in Patients Undergoing Major Esophageal Resection

NCT03115541
View directory record Official record
Conditions
Venous Thromboembolism, Thoracic Surgery, Esophageal Cancer
Interventions
Not listed
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 10, 2026, 1:36 PM EDT
Completed Phase 2 Interventional

Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)

NCT01524653
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Neoplasms
Interventions
Rosuvastatin, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 10, 2026, 1:36 PM EDT
Withdrawn Not applicable Interventional

Heparin Versus no Heparin on Duration of Peripherally Inserted Central Catheter (PICC) Patency in Neonates

NCT00879957
View directory record Official record
Conditions
Infant, Premature, Anticoagulants, Thrombosis
Interventions
heparin, No heparin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Up to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 10, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

NCT02571972
View directory record Official record
Conditions
Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dorzolamide-timolol
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 10, 2026, 1:36 PM EDT
Completed No phase listed Observational Results available

Registry of AngioJet Use in the Peripheral Vascular System

NCT01086215
View directory record Official record
Conditions
Peripheral Vascular Disease, Embolism and Thrombosis, Venous Thrombosis
Interventions
Not listed
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
32
States / cities
Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 10, 2026, 1:36 PM EDT
Recruiting No phase listed Observational

Circadian Variation of Anti-Factor Xa in Hospitalized Trauma Patients

NCT07856641
View directory record Official record
Conditions
Circadian Variation in Anti-Factor Xa (Anti-FXa) Activity
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 10, 2026, 1:36 PM EDT
Terminated No phase listed Observational

Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

NCT01875770
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 10, 2026, 1:36 PM EDT
Completed Not applicable Interventional Results available

Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis

NCT01999179
View directory record Official record
Conditions
Venous Thrombosis, Neoplasms
Interventions
Heparin, Low-Molecular-Weight, or direct oral anticoagulants
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • Columbus, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 10, 2026, 1:36 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Multimodal Physiologic State Intelligence Study

NCT07814118
View directory record Official record
Conditions
Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute, Myocarditis Due to Drug, Myocarditis Viral, Pericardial Diseases, Valvular Heart Diseases, Hypertension, Sepsis, Acute Kidney Injury, Pulmonary Edema - Acute, Pulmonary Edema With Heart Failure, Pulmonary Edemas, Acute Respiratory Distress Syndrome, Pulmonary Embolism Acute, Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute Massive, Pulmonary Embolism Subacute Massive, Venous Thrombosis Pulmonary, Venous Thrombosis (Disorder), Venous Thrombosis, Deep, Peripheral Arterial Disease, Peripheral Arterial Disease (PAD), Aortic Diseases, Muskuloskeletal Diseases, Brain Aging, Brain Aneurysm, Brain Aging Related Conditions, Ultrasound, Ultrasound Exams, Ultrasound Guidance
Interventions
OMNIPHYS Multimodal Ultrasound Imaging System
Device
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2046
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 10, 2026, 1:36 PM EDT
Completed No phase listed Observational

Heparin-Induced Thrombocytopenia Registry

NCT00456326
View directory record Official record
Conditions
Heparin-Induced Thrombocytopenia
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2008 · Synced Oct 10, 2026, 1:36 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Catheter-directed Thrombolysis Compared to Anticoagulation Alone for Acute Primary Iliofemoral Deep Venous Thrombosis

NCT04411316
View directory record Official record
Conditions
Deep Venous Thrombosis, Post Thrombotic Syndrome
Interventions
Catheter directed thrombolysis plus anticoagulation, Anticoagulation
Combination Product · Drug
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 10, 2026, 1:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility Study of Exercise in Patients With Leg Blood Clots

NCT00910364
View directory record Official record
Conditions
Deep Vein Thrombosis
Interventions
Exercise
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
21 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 10, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

A Different Approach to Preventing Thrombosis

NCT02774265
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
VTE prophylaxis with Enoxaparin 30mg BID, VTE prophylaxis with Aspirin 81mg BID
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 10, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

NCT02366871
View directory record Official record
Conditions
Gynecologic Cancer, Venous Thromboembolism
Interventions
Oral apixaban, Subcutaneous enoxaparin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 10, 2026, 1:36 PM EDT